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All herpesviruses contain a tegument layer comprising a protein matrix; these proteins play key roles
during viral assembly and egress. Here, liquid chromatography and tandem mass spectrometry analysis
(LC–MS/MS) of proteins from human herpesvirus 6 (HHV-6)-infected cells revealed a possible association
between two major tegument proteins, U14 and U11. This association was veriﬁed by immunoprecipi-
tation experiments. Moreover, U11 protein was expressed during the late phase of infection and incor-
porated into virions. Finally, in contrast to its revertant, a U11 deletion mutant could not be reconstituted.
Taken together, these results suggest that HHV-6 U11 is an essential gene for virus growth and propa-
gation.
& 2015 Elsevier Inc. All rights reserved.Introduction
Human herpesvirus 6 (HHV-6), which belongs to the Roseolo-
virus genus within the β-herpesvirus subfamily, is a human
pathogen of emerging clinical signiﬁcance (Mori, 2009). HHV-6
was ﬁrst isolated in 1986 from patients with AIDS and lympho-
proliferative disorders (Salahuddin et al., 1986; Weber and Wilson,
1994). HHV-6A and HHV-6B were recently reclassiﬁed as two
different species by the International Committee on Taxonomy of
Viruses (Ablashi et al., 2014; Krug and Pellett, 2014). Primary HHV-
6B infection occurs mainly in young children, and causes exan-
thema subitum and an acute febrile illness (Campadelli-Fiume
et al., 1999; Gewurz et al., 2008; Yamanishi et al., 1988). The
clinical implications of HHV-6A infection, if any, remain unclear.
Previous studies show that reactivation of HHV-6A and HHV-6B in
immunosuppressed patients may contribute to several diseases
(Broccolo et al., 2013; Nora-Krukle et al., 2011; Ogata et al., 2015;
Zerr et al., 2005).
The HHV-6 genome encodes about 100 open reading frames;
some of these are unique to HHV-6, but the functions of others
remain unknown (Dominguez et al., 1999; Gompels et al., 1995;
Mori, 2009; Neipel et al., 1991). The tegument is unique to her-
pesviruses. It is an amorphous structure that occupies the space, Kobe University Graduate
u, Kobe, 650-0017, Japan.
.between the nucleocapsid and the envelope, and encloses many
proteins, called tegument proteins, which play various roles during
virion assembly (Guo et al., 2010; Kelly et al., 2009).
In　HHV-6, U14 encodes the major tegument protein and
shows homology with HCMV UL25 and HHV-7 U14 with approx-
imate identity 25% and 52% respectively (Baldick and Shenk, 1996;
Mori et al., 2015b; Nicholas, 1996; Stefan et al., 1997) HHV-6 U14
binds the tumor suppressor, p53, and incorporates it into viral
particles (Takemoto et al., 2005). Previously, we showed that U14
localizes to the nucleus or cytoplasm depending on the phase of
viral infection (Mori et al., 2015a; Takemoto et al., 2005), and that
it promotes cell cycle arrest in association with E3 ligase identiﬁed
by differential display (EDD) (Mori et al., 2015a). Furthermore, we
found that the U14 gene is essential for the growth of HHV-6 (Mori
et al., 2015b), while HCMV UL25 has been indicated to be dis-
pensable for the growth of AD169 and Towne strains (Dunn et al.,
2003; Yu et al., 2003), HHV-6 U11 encodes tegument protein, p100
in HHV-6A and 101 K in HHV-6B, both of which are major anti-
genic structural proteins (Dominguez et al., 1999; Isegawa et al.,
1999; Neipel et al., 1992; Pellett et al., 1993; Yamamoto et al.,
1990). Since these proteins share only 81% sequence identity at the
amino acid level, they were used to develop an HHV-6 species-
speciﬁc serological assay (Higashimoto et al., 2012). U11 is
homolog to HCMV UL32 that encodes for virion tegument protein
pp150 (antigenic phosphoprotein) (Gompels et al., 1995; Isegawa
et al., 1999; Nicholas, 1996). HCMV UL32 gene is critical for virion
egress (AuCoin et al., 2006) and is essential for virus propagation
(Dunn et al., 2003; Yu et al., 2003); however the detailed function
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interact with one another and are incorporated into virions, and
that the U11 gene is essential for virus propagation. Since HHV-6
U14 and U11 seem to be both abundant tegument proteins, their
interaction may play a crucial role in virion assembly.Results and discussion
All herpesviruses have a characteristic tegument layer, a cluster
of proteins that occupies the space between the capsid and virus
envelope (Guo et al., 2010; Newcomb and Brown, 2010). Since
HHV-6 U14 encodes a major tegument protein, we tried to identify
its characteristic features, detailed functions, and its association
with other viral and cellular proteins. To identify novel proteins
which interact with U14, immunoprecipitation using anti-U14
Mab followed by liquid chromatography and tandem mass spec-
trometry (LC–MS/MS) analysis of proteins derived from HHV-6-
infected cells was performed. Obtained results revealed possible
interactions between U14 and viral and cellular proteins. Cellular
proteins, p53 and EDD, were mainly detected as reported pre-
viously (Mori et al., 2015a; Takemoto et al., 2005), and U11 was
also detected as one of viral proteins. Therefore, we focused on the
analysis of the interaction between U14 and U11.
To analyze their interaction, ﬁrst, 293T cells was transfected
with pCAGGS/U11 and U14 or with pCAGGS/U14, pCAGGS/U11, or
pCAGGS alone (empty vector). We immunoprecipitated cell lysates
with U14 Mab, followed by western blot analysis of the pre-
cipitated proteins. As shown in Fig. 1A, U14 co-precipitated with
U11. Unfortunately the U11 Mab used for immunoprecipitationFig. 1. Interaction between HHV-6 U14 and U11 in transfected and infected cells (A) 2
pCAGGS (empty vector) as indicated. Cells were then harvested, lysed, and subjected to i
14 and anti-11 Mabs. Left and right panels shows the results in case of HHV-6 A and HHV
subjected to immunoprecipitation with anti-U14 (left) and anti-U11 (right) Mabs, then w
panels indicate molecular masses.could not be available for lysate of U11-transfected cells, but not
for that of infected cells, although no reason has been found so far.
Therefore, we conﬁrmed their interaction using HHV-6A-infected
and mock-infected HSB-2 cells. Obtained results of immunopre-
cipitation experiments with anti-U14 or -U11 Mabs conﬁrm the
reciprocal interaction between these two tegument proteins in
HHV-6A-infected cells (Fig. 1B). This interaction is ﬁrstly identiﬁed,
and such interaction has not been reported between their homo-
logs HCMV UL25 and UL32.
From this point on, we decided to examine the function of HHV-6A
U11 in more detail. HHV-6 U11 comprises immunodominant tegu-
ment proteins, p100 and 101 K (Dominguez et al., 1999; Isegawa et al.,
1999; Neipel et al., 1992; Pellett et al., 1993; Yamamoto et al., 1990),
which were used to generate species- speciﬁc immunoblotting assay
that could discriminate between HHV-6A and HHV-6B (Higashimoto
et al., 2012).
First, we analyzed the kinetics of U11 protein expression. HSB-2
cells were infected with HHV-6A GS and then harvested at dif-
ferent times. An approximately 100 kDa protein was detected.
Expression of U11 protein gradually increased over two days post
infection (p.i) (Fig. 2A). The gB protein was used as a positive
control for infection. A more detailed analysis was performed by
infecting cells with HHV-6A GS in the presence/absence of phos-
phonoformic acid (PFA) that inhibits viral DNA replication (Wah-
ren and Eriksson, 1985; Zahn et al., 2011) In the presence of PFA,
U11 expression was markedly reduced, as was that of late phase
proteins gB and gL (Fig. 2B). These results suggest that U11 is also a
late phase protein similar to its homolog, HCMV UL32, which has
been shown to be accumulated during late phase of the infectious
cycle　(Meyer et al., 1997; Zipeto et al., 1993).93 cells were transfected with pCAGGS/U11þU14, pCAGGS/U14, pCAGGS/U11, or
mmunoprecipitation with an anti-U14 Mab followed by western blotting with anti-
-6 B respectively. (B) Mock- and GS-infected HSB-2 cells were harvested, lysed, and
estern blotting. IP, immunoprecipitation; WB, western blot. The numbers beside the
Fig. 2. Kinetic analysis of U11 protein expression (A) HSB-2 cells were infected with the GS strain and harvested at different time intervals (0–96 h p.i). Cell lysates were
analyzed on 7.5% SDS-PAGE gels under reducing conditions, followed by western blot analysis with anti-AU11 and anti-gB antibodies. (B) GS-infected HSB-2 cells cultured
with/without PFA (80 or 320 μg ml1) were harvested at 2 and 4 days p.i. Cell lysates were prepared and separated by SDS-PAGE, followed by western blotting with anti-
AU11, anti-gB, or anti-gL antibody. p.i, post-infection; WB, western blot.
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agreement with previous reports that U11 is abundantly present in
virions in case of HHV-6A (strain U1102) and HHV-6B (strain Z29)
(Neipel et al., 1992; Yamamoto et al., 1990). We also examined it
here. Thus virions released from HHV-6A-infected cells were
puriﬁed using the two-step Nycodenz gradient method. Collected
fractions were then analyzed by polymerase chain reaction (PCR)
and subjected to western blot analysis. U11 was detected in frac-
tions containing virions (fractions 6–8) (Fig. 3).
Next, we asked whether U11 is essential for virus growth. We
constructed U11 mutant virus by deleting 144 base pair (bp) from
the U11 gene sequence. Only 144 bp were deleted because delet-
ing the entire sequence may adversely affect the promotor region
of U12 (Fig.4).
The deleted region was randomly selected within U11 sequence
(1156–1300 bp) because no distinct region was found upon ana-
lyzing of the predicted secondary structure of U11 protein. Sec-
ondary structure prediction was done using the self-optimized
prediction method with alignments (SOPMA) (http://npsa-pbil.
ibcp.fr)(Geourjon and Deleage, 1995). Regarding to the expected
sequence of deletion mutant, its translated product would be
about 390 amino acid (aa) stopping at 1170 bp although predicted
size of full length is 870 aa (Fig.4).
The deletion mutant and revertant were constructed using the
same method. Then, the resultant bacterial artiﬁcial chromosome(BAC) DNAs (HHV-6ABACΔU11 and HHV-6ABACΔU11rev) were
extracted and digested with BamH1. As predicted, very similar
digestion patterns were observed (data not shown). J Jhan cells
were transfected with resultant BAC DNAs or HHV-6ABAC (wild
type) and then co-cultured with umbilical cord blood mono-
nuclear cells (CBMCs). Positive cells were detected after 4–5 days.
After three rounds of cell-to-cell infection, we observed a marked
increase in green ﬂuorescent protein (GFP) expression only in
HHV-6ABAC (wild type) and HHV-6ABACΔU11rev (Fig. 5A). To
conﬁrm expression of viral genes, cells were harvested and pre-
pared for western blot analysis. U11 expression was detected in
HHV-6ABACΔU11rev-infected cells, indicating that the U11 dele-
tion revertant was successfully assembled (Fig. 5B).
These ﬁndings suggest that partial deletion of U11 from the
HHV-6A genome leads to a failure of viral reconstitution. Similar
results have been previously reported for HCMV UL32 deletion
mutants (Dunn et al., 2003; Yu et al., 2003).
Previous reports (AuCoin et al., 2006; Dunn et al., 2003; Meyer
et al., 1997; Yu et al., 2003; Zipeto et al., 1993) and our results
suggest that two homologs, HHV-6 U11 and HCMV UL 32, may
share some properties. For instance, UL 32 is tegument protein
that has been reported to be important for virion egress (AuCoin
et al., 2006); also U11 is a tegument protein, and our current
results show that it may play similar role during HHV-6 virion
envelopment. Further studies would be required to conﬁrm this.
Fig. 3. Puriﬁcation of HHV-6A virions and western blotting to detect U11 (A) PCR of
viral DNA in protein fractions puriﬁed using the Nycodenz gradient centrifugation
method. Fractions 6–8 were positive for U11. (B) Puriﬁed fractions were analyzed
by immunoblotting with anti-AU11, anti-U14, anti-gB or anti-IE1 antibodies. The
numbers above each lane represent the fraction number from gradient puriﬁcation.
Fig. 4. Construction of a U11 deletion mutant and predicted outcomes on trans-
lated protein Schematic representation of HHV-6ABACΔU11, showing the full
length U11 (wild type), truncated U11, and part of predicted amino acid sequence of
truncated protein. The deleted section (1156–1300 base pairs) is indicated by the
dotted lines. TGA is stop codon.
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duals on three separate occasions, with the same result.
In summary, HHV-6A U11 and U14 are two tegument proteins
that interact with each other. This interaction may play a role in
the tegumentation process during virus infection. Further detailed
studies are required to examine the biological importance of these
proteins.
Taken together, the results presented herein show that U11 is a
virion protein expressed at the late phase of viral infection and
plays a crucial role during virus growth and propagation.Materials and methods
Cells and virus strains
T cell lines (J Jhan, HSB-2, and MT4) were cultured in RPMI 1640
medium supplemented with 8% fetal bovine serum (FBS). The
human embryonic kidney cell line 293T was maintained in Dul-
becco's modiﬁed Eagle's medium supplemented with 8% FBS.
CBMCs were provided by H. Yamada (Kobe University Graduate
School of Medicine, Kobe, Japan) and purchased from the Cell Bank
of the RIKEN BioResource Center, Japan, and cultured in RPMI
medium containing 10% FBS, phytohemagglutinin (PHA; 5 μg/ml),
and interleukin-2 (IL-2; 2 ng/ml) (Oyaizu et al., 2012). CBMCs were
used for viral propagation, as previously described (Mori et al.,
2004). Regarding CBMC usages, the study was approved by the
ethics committee of Kobe University Graduate School of Medicine.
HHV-6A strains GS and U1102, and HHV-6B strain HST were
propagated in HSB-2, J JHAN, and MT4 cells, respectively. HSB-2
cells were infected with HHV-6A GS and cultured in medium with
and without PFA (80 or 320 μg ml1, Sigma-Aldrich). PFA inhibits
the synthesis of viral late genes (Hayashi et al., 2014).Antibodies
Monoclonal and polyclonal antibodies speciﬁc for HHV-6A
were generated by immunizing BALB/c mice or rabbits with a
maltose-binding protein–U11 fusion. PCR was conducted using
primers AU11m1684BamH1F and AU11m XhoR (Table 1). The
ampliﬁed product was digested with BamHI and XhoI, and inser-
ted in-frame into the pMAL-c2 bacterial expression vector (New
England Biolabs) (Table, BamHI and XhoI sites underlined). The
recombinant proteins were expressed at 30 °C in E. coli (BL21) and
puriﬁed on amylose beads (New England Biolabs), according to the
manufacturer's instructions.
A polyclonal antibody against gB and Mabs speciﬁc for HHV-6
U14, gL (AgL3), gQ1 (AgQ-119) and IE1 have been previously
described (Akkapaiboon et al., 2004; Huang et al., 2006; Mori
et al., 2003, 2008; Takemoto et al., 2005). A Mab speciﬁc for HHV-
6B P101, encoded by U11, has been previously reported (Pellett
et al., 1993; Yamamoto et al., 1990) and was purchased from Mil-
lipore (clone: MAB8535).Western blot analysis
Samples were separated by SDS-PAGE, electrotransferred onto
PVDF membranes, and reacted with primary antibodies as
described previously (Akkapaiboon et al., 2004). Reactive bands
were detected using a horseradish peroxidase-linked secondary
conjugate (GE Healthcare Biosciences) and visualized using
enhanced chemiluminescence (ECL) reagents.
Immunoprecipitation and LC–MS/MS analysis
Mock- or HHV-6B strain HST-infected MT4 cells were lysed in
TNE buffer (10 mM Tris–HCl [pH 7.8], 0.15 M NaCl, 1 mM EDTA, and
1% NP-40) at 96 h post-infection (p.i.). Immunoprecipitations were
performed using anti-U14 Mab conjugated to protein G Sepharose
(GE Healthcare Biosciences) via dimethyl pimelimidate (DMP;
Thermo Scientiﬁc). Whole cell extracts were then incubated with
the protein G-Sepharose-bound antibody. Bound proteins were
eluted with 0.1 M glycine (pH 2.8) and neutralized with 1 M Tris-
HCl (pH 9.5). Eluted proteins were prepared for LC/MS analysis as
previously described (Nakamura et al., 2008).
Fig. 5. GFP expression in reconstituted virus-infected cells and conﬁrmation of viral protein expression (A) Isolated BAC DNAs were transfected into JJhan cells, which were
then co-cultured with CBMCs on Day 4 post-transfection. Light microscopic images are shown on the left and GFP-ﬂuorescence images are shown on the right. Upper panel:
HHV-6ABAC “wild type’’; Lower panel: HHV-6ABACΔU11rev. (B) To conﬁrm viral protein expression, transfected JJhan cells were subjected to three rounds of cell-to-cell
infection with CBMCs. Cell lysates were resolved by SDS-PAGE under reducing conditions, and then blotted with U11 (left) and AgQ-119 (right) Mabs. Uninfected CBMCs
served as a negative control.
Table 1
Primer sequence.
Primer name Sequence
AU11m1684BamH1 F 5-aacggatcccccaagtccctgaccaaag-3
AU11mXhoR 5-accctcgagttagctggcaatggcgctctc-3
AU11del 1156F 5-agcgacaacgcctgcttcctctgtctctttaatgtccggacacctaatgcgcaattgaataggatgacgacgataag-3
AU11del 1300R 5-tagtaaatccacaccgttcgtattcaattgcgcattaggtgtccggacattaaagagacagcaaccaattaaccaattc-3
AU11 841F 5-agcgcgtcgaaagcattttcg-3
Kan 388R 5-tccgtcagccagtttagtctg-3
AU11 1948R 5-ctttatcgtcattaaactttc-3
AU11 1109F 5-acgttaaagcgacaacg3
AU11 11300BamH1 R 5-accggatccgaaatttaacattaaaatc-3
Kan BamH1 F 5-acaggatccaggatgacgacgataagtag-3
AU111156rev part2R1 5-ctaaaatccccgaagggccaattttcaaccaattaaccaattc-3
AU111156rev part2 R2 5-gtattcaattgcgcattaggtggaaatttaacattaaaatctaaaatccccgaagggcc-3
AU111156re part2 R3 5-gtagtaaatccacaccgttcgtattcaattgcgcatta-3
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The pCAGGS vector (a kind gift from Jun-ichi Miyazaki, Osaka
University, Japan) was used to construct plasmids containing U14
and U11 as previously described (Niwa et al., 1991), and codon-
optimized U11 and U14 were used in this study. The resulting
constructs were validated by DNA sequencing, 293T cells were
then transfected with the plasmids using the calcium phosphate
method, as described previously (Koshizuka et al., 2010).Puriﬁcation of HHV-6 virions
HSB-2 cells were infected with the GS strain, and at 3–4 days p.
i, cell-to-cell infection was performed (Kawabata et al., 2009).Vir-
ions were then puriﬁed on a Nycodenz gradient as previously
described (Kawabata et al., 2009). Finally, collected fractions were
examined with ampliﬁcation of glycoprotein B gene by PCR. In
addition, fractions were analyzed by western blotting with anti-
AU11, anti-U14, anti-gB and anti-IE1 antibodies.
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The two-step Red-mediated recombination system in E. coli
(Tischer et al., 2006) was used to construct the AU11 deletion
mutant and its revertant (Hayashi et al., 2014; Oyaizu et al., 2012;
Tang et al., 2010). The sequences of the primers used during the
construction procedure are listed in Table 1. Brieﬂy, 600 ng of the
PCR product was ampliﬁed from the plasmid pEP-KanS using
primers AU11del 1156 F and AU11del 1300 R, and then trans-
formed into GS1783-competent cells (harboring the HHV-6A BAC)
using a Bio-Rad E. coli Pulser (Bio-Rad laboratories; Inc). The
bacteria were then cultured at 30 °C for 2 h and plated onto LB
agar plates containing chloramphenicol (17 μg/ml) and kanamycin
(50 μg/ml) to facilitate selection of E. coli clones harboring the
kanamycin-resistance gene. The selected clones were conﬁrmed
by PCR using primers AU11 841F and Kan 388R. Next, the
kanamycin-resistance gene was excised via expression of the I-
Sce1 restriction enzyme, which was triggered by arabinose. The
Red recombination machinery was then activated by raising the
temperature. Brieﬂy, 100 μl of an overnight culture of GS1783 cells
containing the kanamycin-resistance-gene-harboring HHV-6ABAC
was inoculated into 2 ml of LB medium containing chlor-
amphenicol. Bacteria were incubated for 4 h at 30 °C before 10%
(wt/vol) L-arabinose was added to the culture at ratio of 1:4 (vol /
vol). After incubating for 1 h, the culture was transferred to a 42 °C
water bath and incubated for a further 30 min. The culture was
then shaken at 30 °C for another 2 h before 100 μl of culture
(diluted 103–106) was plated onto LB agar plates containing
chloramphenicol. After 24–48 h, individual colonies were streaked
in duplicate on chloramphenicol- and chloramphenicol–kanamy-
cin-containing plates.
Chloramphenicol-resistant/kanamycin-sensitive clones were
ﬁrst screened by PCR using primers AU11 841F and AU11 1948R,
followed by nucleotide sequencing to conﬁrm deletion of the
desired section of the kanamycin-resistance gene. The resultant
BAC was named HHV-6ABACΔU11.
Next, an AU11 deletion revertant was constructed as follows.
The deleted portion of AU11 was ampliﬁed from the U1102 gen-
ome using primers AU11 1109F and AU11 11300BamH1R. The
kanamycin-resistance gene from pEP-KanS was then ampliﬁed by
two subsequent rounds of PCR; the ﬁrst round used primers Kan
BamH1F and AU11 1156rev part2 R1 and the second round used
the same forward primer and AU111156rev part2 R2
The two ampliﬁed DNA fragments were digested with BamH1,
ligated, and ampliﬁed with AU111109F and AU111156rev part2 R3.
Next, 500 ng of PCR product was transformed into GS1783 E. coli
electroporation-competent cells containing HHV-6ABACΔU11. The
selected clones were conﬁrmed by PCR using two sets of primers:
AU11 841F and AU111948R and AU11 841F and Kan388R. Next, the
kanamycin-resistance gene was excised by expressing the I-Sce1
restriction enzyme followed by induction of the Red recombina-
tion system as described above. Finally, AU11 deletion revertant
(HHV-6ABACΔU11rev) DNA was isolated and validated by PCR
using primers AU11 841F and AU111948R followed by sequencing.Extraction and analysis of BAC plasmids
BAC DNA was isolated from E. coli using the Macherey-Nagel
NucleoBond Bac100 puriﬁcation kit. Extracted DNA was digested
with BamH1 and separated on a 0.5% agarose gel.
Reconstitution of infectious virus
Infectious virus was reconstituted using puriﬁed HHV-6A BACs
as previously described (Tang et al., 2011, 2010).Acknowledgment
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